KRAS and non-small cell lung carcinoma: Consistent with these findings, KRAS;LKB1-mutated NSCLC patients exhibited lower infiltration of cytotoxic T cells into the TME and resistance to anti-PD-1 therapy [117] possibly because the secretion of type I interferon and CXCL10 downstream of STING plays a critical role in the anti-tumorigenic response following ICB.